Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + Thalidomide in HER2 Exon 20 Insertion NSCLC
NCT04382300Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Jun 2020
- Primary completion
- Oct 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04382300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382300.